How Chandler Crews defied controversy, gained 13 inches, and became a beacon of hope for the achondroplasia community

A Life-Changing Decision at 16
When Chandler Crews stood at just 3 feet 10 inches tall at age 16, every aspect of daily life presented a challenge. Simple tasks that most people take for granted—washing her hair, driving safely, using public restrooms—required creative problem-solving or assistance. Born with achondroplasia, the most prevalent form of dwarfism affecting approximately 1 in 10,000 births, Crews faced not just physical obstacles but also severe medical complications including bowed legs and chronic ear infections.
But in 2010, the Maryland teenager made a decision that would transform her life and spark heated debate within the dwarfism community: she chose to undergo extensive limb lengthening surgery at the International Center for Limb Lengthening at Baltimore’s Rubin Institute for Advanced Orthopedics.
“I was just tired of having my height define me,” Crews explained in interviews. At 3’10”, she had already reached her full adult height for someone with achondroplasia—below even the average of 4’1″ for women with the condition. She wasn’t waiting for the world to change around her; she was taking control of her own future.
The Journey: Four Years, Multiple Surgeries, 13 Inches
What followed was an arduous four-year journey involving multiple surgical procedures. Crews underwent leg lengthening operations to correct her severely bowed legs and add height, followed by arm lengthening surgeries that gave her an additional 4 inches of reach. The procedures, which can cost upward of $100,000, were largely covered by insurance because they offered legitimate medical benefits beyond cosmetic improvements.
The surgeries worked through a process called distraction osteogenesis. Doctors make precise cuts in the bones—first the femurs, then the tibias and fibulas—and gradually pull them apart using external fixators or, in later procedures, internal telescoping rods. New bone forms in the gap, effectively lengthening the limb. It’s a meticulous process requiring months of recovery, physical therapy, and constant adjustments.
By the end of her treatment, Crews had gained an remarkable 13 inches, reaching just under 5 feet tall—specifically, 4’11¾”. The transformation went far beyond the numbers on a measuring tape.
More Than Just Height: The Hidden Benefits
While critics focus on the cosmetic aspects, Crews emphasizes the profound functional and psychological improvements. Tasks that were once daily struggles became manageable. She could style her own hair without assistance. Driving became safer as she could sit further from the steering wheel. Personal hygiene routines no longer required elaborate accommodations.
But perhaps the most significant change was something she hadn’t anticipated: eye-level communication. “Being able to just walk up to someone and communicate with my face in the same range as their face has been the biggest game changer for me,” Crews shared. This simple ability—to converse face-to-face rather than hip-to-face—transformed her social interactions and confidence.
The medical benefits were equally important. The procedures helped reduce the hyperlordosis (excessive inward curvature) of her spine, which can reduce pressure on the spinal cord and decrease the risk of spinal stenosis. Straightening her bowed legs improved joint alignment and could help prevent early-onset arthritis.
Navigating Controversy in Her Own Community
Limb lengthening for achondroplasia remains deeply controversial, particularly within North American dwarfism advocacy groups like Little People of America. According to a 2024 international survey of 467 individuals with achondroplasia, only 19.3% reported undergoing the procedure. The debate centers on whether the surgery represents self-acceptance or self-rejection.
Critics argue that limb lengthening sends a message that dwarfism is something to be “fixed” rather than embraced. At a Little People of America convention, some advocates wore shirts reading “Short by birth, staying that way by choice,” making their stance clear. A petition circulated asking advocacy groups to denounce the procedure as painful and primarily cosmetic.
Crews has faced ostracism from some in her own community. “The argument is that those of us who choose to undergo lengthening are unhappy with who we are—we want to change ourselves, we don’t want to have dwarfism,” she has said. “I will always have dwarfism. There’s absolutely nothing that can ever change that.”
She describes herself now as a “comfortable short,” refusing to apologize for her personal decision while respecting others’ choices to forgo surgery. Interestingly, while the procedure remains controversial in the United States and Canada, it’s widely accepted as a legitimate treatment option in Europe, Asia, and South America.
From Patient to Advocate: The Chandler Project
Crews transformed her personal experience into a mission. Breaking with the tradition of patient stories being shared only after-the-fact, she documented her entire journey in real-time on social media, creating transparency at a time when information about limb lengthening for dwarfism was outdated and scarce.
This transparency evolved into The Chandler Project, a nonprofit organization she founded to support individuals with achondroplasia and other skeletal dysplasias. As a 501(c)(3) organization, it serves as the only patient advocacy group in North America dedicated solely to providing the latest information on pharmaceutical research and surgical advancements for skeletal dysplasias.
The organization’s mission is personal: “I want to always be the person that my parents wish they had had when I was diagnosed and born,” Crews explains. When she was born in 1993, the gene causing achondroplasia hadn’t even been discovered yet. Her parents navigated a pre-Google world with limited resources and often contradictory information.
Today, families facing a new achondroplasia diagnosis have access to resources Crews’s parents never had. The Chandler Project connects them with world-renowned researchers and physicians, provides up-to-date scientific information, and offers community support through events like PHARMACHON, the premier annual conference in North America for skeletal dysplasia research and advocacy.
A Changing Landscape: New Treatments on the Horizon
The timing of Crews’s advocacy couldn’t be more crucial. The treatment landscape for achondroplasia is experiencing unprecedented transformation. When Crews had her surgeries in 2010, limb lengthening was essentially the only option for addressing height concerns. Today, multiple pharmaceutical interventions are in various stages of development and approval.
Vosoritide, a C-type natriuretic peptide analog, became the first precision drug approved for achondroplasia treatment. Recent research shows it not only increases annualized growth velocity but also improves physical and social aspects of health-related quality of life. However, it requires daily injections.
In June 2025, TransCon CNP (navepegritide) demonstrated significantly higher annualized growth velocity compared to placebo in clinical trials and received FDA Priority Review designation. As a once-weekly injection, it promises to reduce treatment burden.
Newer oral medications are also emerging. TYRA-300, the first oral FGFR3-selective inhibitor well-tolerated in clinical studies, received FDA clearance to proceed with pediatric trials, with the first children expected to be dosed in early 2025. Another compound, KY-065, targets a different pathway and has shown promise in animal models.
“To think about 10 years ago, there were no companies other than BioMarin researching achondroplasia,” Crews reflects. “Now parents who have children born with achondroplasia today have more opportunities for their child than my parents ever did.”
Professional Evolution: Working Within the System
Crews’s journey has evolved into a career as a patient engagement and communications professional. She now works as an Orthopedic Care Coordinator and Liaison at Nemours Children’s Hospital in Orlando—the same institution where her surgeon now practices. She also receives spine monitoring care there from leading specialists.
Her unique perspective—as someone who has lived with achondroplasia, undergone extensive treatment, and now works within the medical system—makes her an invaluable resource for families navigating similar decisions. She helps families explore options ranging from pharmaceutical interventions to surgical treatments, always emphasizing that these are deeply personal choices.
The Medical Reality: Understanding Achondroplasia
Achondroplasia results from a mutation in the FGFR3 gene, which affects how cartilage converts to bone during development. The condition is characterized by short stature with an average-sized torso but shortened arms and legs (rhizomelic dwarfism), along with distinctive features including a prominent forehead and flattened nasal bridge.
Beyond stature issues, achondroplasia can cause serious medical complications throughout life. Infants may experience foramen magnum stenosis (narrowing at the base of the skull) that can compress the spinal cord. Children frequently require ear tubes due to chronic infections. Spinal stenosis, sleep apnea, bowed legs, and joint problems are common. Some individuals require spinal fusions, decompressions, or other major interventions.
It’s crucial to understand that limb lengthening doesn’t change the genetic condition itself. Crews still has achondroplasia and still faces the same potential health risks. The surgery addresses orthopedic and functional issues but doesn’t alter her DNA or prevent her from potentially passing the condition to future children.
The Cost-Benefit Analysis
Medical literature reveals that limb lengthening for achondroplasia carries significant risks. A 2024 international survey found that while patients reported substantial functional improvements—particularly those who had both arm and leg lengthening—the recommendation rate was surprisingly mixed. Only 23% would recommend the procedure to others, 28% would not recommend it, and 49% were uncertain.
Complications can include joint stiffness, fractures, infections, nerve damage, and in rare cases, more serious issues. One study reported a case of paraparesis (partial paralysis) following surgery. The average patient undergoes 3.7 procedures with healing periods spanning months or years.
Yet for many, the benefits outweigh the risks. Research shows improvements in daily activities like driving, bathing, grooming, and personal hygiene. The psychological benefits of improved body proportions and increased independence can be profound. Studies indicate that extensive limb lengthening doesn’t typically lead to long-term joint degeneration when performed with modern techniques and strict protocols.
Looking Forward: Empowerment Through Information
Fifteen years after her first surgery, Crews continues expanding her impact. The Chandler Project recently partnered with QED Therapeutics to create MyAchonJourney, an educational resource supporting families from pregnancy through a child’s first five years of life. The organization hosts annual conferences bringing together researchers, physicians, families, and pharmaceutical companies to share cutting-edge science and lived experiences.
Crews’s message is consistent: families should have access to comprehensive, accurate information about all available options—pharmaceutical, surgical, and supportive care—without judgment. She emphasizes meeting medical teams in person, understanding the commitment required, and making informed decisions based on individual circumstances and values.
“This type of surgery is only performed at a few centers in the world,” she notes. “It’s a big commitment for the patient and their family. It’s hard work, and it’s important to be 100% comfortable with your medical team because you’ll be working together with them to get the best results.”
A Personal Choice With Universal Implications
Chandler Crews’s story illustrates the complex intersection of medical innovation, personal autonomy, and community values. Her decision to undergo limb lengthening was deeply personal, driven by a desire for functional independence and improved quality of life. The fact that it remains controversial within her own community doesn’t diminish the validity of her choice—or the choices of those who opt differently.
What makes her journey particularly valuable is her commitment to transparency and advocacy. By sharing her experience openly, she’s helped demystify a procedure that was shrouded in outdated information. By founding The Chandler Project, she’s created a lifeline for families navigating difficult decisions.
As pharmaceutical options expand and surgical techniques improve, the landscape for achondroplasia treatment will continue evolving. But the fundamental principle remains: individuals and families deserve access to comprehensive information, compassionate medical care, and the freedom to make choices aligned with their values and goals.
Standing at nearly 5 feet tall, Chandler Crews has literally and figuratively risen above limitations others might have accepted. Her message isn’t that everyone should make the same choice she did—it’s that everyone should have the opportunity to choose, supported by the best available science and the strength of community.